drugset

drugset / Trial / NCT04922138

Aumolertinib Adjuvant Therapy of Resectable Stage I EGFRm+ NSCLC With High-grade Patterns

NCT04922138 ↗

Phase 2 Unknown 104 enrolled Baohui Han Jiangsu Hansoh Pharmaceutical Co., Ltd. · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

Efficacy and safety of postoperative adjuvant treatment of NSCLC patients with Aumolertinib.

Timeline

Start: 2022-01-14
Primary completion: 2024-04-15
Completion: 2025-10-15

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Almonertinib	Small molecule	110 mg	Oral

Indications